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Abstract
To investigate which matrix metalloproteinases (MMPs) are more likely to be involved in the angiogenic process in
proliferative diabetic retinopathy (PDR), we measured the levels of MMPs in the vitreous fluid from patients with PDR
and controls and correlated these levels with the levels of vascular endothelial growth factor (VEGF). Vitreous
samples from 32 PDR and 24 nondiabetic patients were studied by mosaic multiplex MMPs enzyme-linked
immunosorbent assay (ELISA), single ELISA, Western blot and zymography analysis. Epiretinal membranes from 11
patients with PDR were studied by immunohistochemistry. MMP-8 and MMP-13 were not detected. ELISA, Western
blot and gelatin ymography assays revealed significant increases in the expression levels of MMP-1, MMP-7, MMP-9
and VEGF in vitreous samples from PDR patients compared to nondiabetic controls, whereas MMP-2 and MMP-3
were not upregulated in vitreous samples from PDR patients. Significant correlations existed between ELISA and
zymography assays for the quantitation of MMP-2 (r=0.407; p=0.039) and MMP-9 (r=0.711; p<0.001). Significant
correlations were observed between levels of VEGF and levels of MMP-1 (r=0.845; P<0.001) and MMP-9 (r=0.775;
p<0.001), and between levels of MMP-1 and MMP-9 (r=0.857; p<0.001). In epiretinal membranes, cytoplasmic
immunoreactivity for MMP-9 was present in vascular endothelial cells and stromal monocytes/macrophages and
neutrophils. Our findings suggest that among the MMPs measured, MMP-1 and MMP-9 may contribute to the
angiogenic switch in PDR.
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Introduction
Proliferative diabetic retinopathy (PDR), a long-term
complication of diabetes, is characterized by vasculopathy
associated with abnormal angiogenesis and expansion of
extracellular matrix (ECM) resulting in the outgrowth of
fibrovascular membranes at the vitreoretinal interface.
Formation of fibrovascular tissue results in severe
complications such as vitreous hemorrhage and traction retinal
detachment. Angiogenesis, the sprouting of new blood vessels
from preexisting blood vessels, is a multistep process requiring
the degradation of the basement membranes and ECM,
endothelial cell migration, endothelial cell proliferation, and
capillary tube formation [1]. Vascular endothelial growth factor
(VEGF) is the major angiogenic factor in PDR that promotes
neovascularization and vascular leakage [2].
The angiogenic switch involves in part the proteolytic
degradation of basement membranes and ECM components
by matrix metalloproteinases (MMPs). In addition to removing
the physical barriers to new vessel growth, MMPs
proteolytically release VEGF from the ECM-associated
reservoirs [3,4], resulting in increased VEGF bioavailability and
triggering the VEGF-driven angiogenic switch [3,4]. MMPs are
a family of zinc ion-binding Ca2+-dependent neutral
endopeptidases that act together or in concert with other
enzymes to degrade most components of the ECM. At least 25
MMP members have been indentified and are divided into
collagenases (MMP-1, MMP-8, and MMP-13), gelatinases
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(MMP-2, and MMP-9), stromelysins (MMP-3, MMP-10, and
MMP-11), matrilysins (MMP-7, and MMP-26), membrane-type
MMPs, and others [5]. Most of the MMPs are inhibited by
specific endogenous tissue inhibitors which are known as
tissue inhibitors of matrix metalloproteinases (TIMPs) [5].
Under steady state physiologic conditions, the expression of
MMPs in most tissues is relatively low, with the possible
exception of MMP-2, which appears to be expressed
constitutively [1]. These enzymes have been implicated in
invasive cell behavior and recent studies have indicated that
MMPs are generally up-regulated in several conditions that
accompany angiogenesis and play an important role in the
initiation of angiogenesis [1]. In PDR, the levels of certain
MMPs are increased dramatically [6-9]. This up-regulation of
MMPs is linked to angiogenesis and progression of PDR.
However, the relative relevance of individual MMPs to
angiogenesis associated with PDR remains to be elucidated.
To develop efficient specific inhibitors for anti-angiogenic
therapy, it is necessary to know which MMPs are more likely to
be involved in the angiogenic process in PDR. Therefore, we
measured the levels of the MMPs MMP-1, MMP-2, MMP-3,
MMP-7, MMP-9, and MMP-13 in the vitreous fluid from patients
with PDR and nondiabetic patients and correlated their levels
with the levels of the angiogenic factor VEGF. The association
of MMPs with VEGF is likely to be an indicator of the relevance
of MMPs to angiogenesis and diabetic retinopathy.
Materials and Methods
Ethics statement
The study was conducted according to the tenets of the
Declaration of Helsinki. All the patients were candidates for
vitrectomy as a surgical procedure. All patients signed a
preoperative informed written consent and approved the use of
the excised epiretinal membranes and vitreous fluid for further
analysis and clinical research. The study design and the
protocol was approved by the Research Centre and
Institutional Review Board of the College of Medicine, King
Saud University.
The sections from the control patients were obtained from
patients treated at the University Hospital, University of
Leuven, Belgium, in full compliance with tenets of the
Declaration of Helsinki. We used archived material and patients
gave written consent at admission for the use of the leftover
material in studies. The Ethics Committee of the University
Hospital, University of Leuven approved this consent
procedure.
Vitreous samples and epiretinal membrane specimens
Undiluted vitreous fluid samples (0.3 - 0.6 ml) were obtained
from 32 patients with PDR during pars plana vitrectomy. The
indications for vitrectomy were traction retinal detachment,
combined traction/rhegmatogenous retinal detachment, and/or
nonclearing vitreous hemorrhage. The control group consisted
of 24 patients who had undergone vitrectomy for the treatment
of rhegmatogenous retinal detachment with no proliferative
vitreoretinopathy. Controls were free from systemic disease.
Vitreous samples were collected undiluted by manual suction
into a syringe through the aspiratin line of vitrectomy, before
opening the infusion line. The samples were centrifuged (5000
rpm for 10 min, 4°C) and the supernatants were aliquoted and
frozen at -80°C until assay. Epiretinal fibrovascular membranes
were obtained from 11 patients with PDR during pars plana
vitrectomy for the repair of traction retinal detachment.
Membranes were fixed in 10% formalin solution and embedded
in paraffin.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) kits for a
panel of specific human MMPs panel (mosaic multiple matrix
metalloproteinases, Cat No: MEA006), Human MMP-2
(Quantikine MMP-2, Cat No: DMP2F0) and human VEGF
(Quantikine Human Vascular Endothelial Growth Factor, Cat
No: DVE00) were purchased from R&D Systems, Minneapolis,
MN.
The mosaic human MMPs panel immunoassay
simultaneously detects seven MMPs with members of the
collagenase (MMP-1, MMP-8, MMP-13) the gelatinase
(MMP-2, MMP-9), the stromelysin (MMP-3) and the matrilysin
(MMP-7) subgroups. The detection limit for each MMP using
MMPs panel ELISA kit was 28, 120, 4, 2, 22, 45, and 36
picograms/mL (pg/mL) for MMP-1, MMP-2, MMP-3, MMP-7,
MMP-8, MMP-9, and MMP-13, respectively. The detection
limits for MMP-2 single ELISA kit and VEGF ELISA kit were 47
pg/mL and 5 pg/mL, respectively. The ELISA plate readings
were done using FLUOstar Omega-Microplate reader from
BMG Labtech, Offenburg, Germany.
Measurement of human MMPs
The detection and quantification of MMPs in the vitreous fluid
was done using mosaic multiplex MMPs ELISA kit according to
the manufacturer’s instruction. An amount of 50 µL of cocktail
of recombinant human MMPs standard and undiluted vitreous
fluid, respectively, were added to each well of the ELISA plate.
The assay was performed in duplicate for each standard and
vitreous sample. The plates were incubated and washed
followed by the addition of detection antibody. After incubation
and washing, the Streptavidin-HRP was added into each well.
Immunoreactivity for each MMP was visualized as spot on a
high-performance chemiluminescence machine (G: Box
Chemi-XX8, Cambridge, UK) by the addition of enhanced
chemiluminescence plus substrate and quantified by
densitometric analysis using image processing and analysis in
GeneTools (Syngene by Synoptic Ltd. Cambridge, UK). The 5-
parameter fit logistic (5-PL) curve equation (MasterPlex EX
2010 software, Hitachi, San Francisco, CA) was used for
making the standard curve and the actual concentration for
each sample was calculated.
Measurement of human MMP-2 and VEGF
The quantification of MMP-2 and VEGF in the vitreous fluid
was determined using ELISA kits according to the
manufacturer’s instruction. For each ELISA kit, an undiluted
standard served as the highest standard level and the
calibrator diluents served as the zero standard. Depending
upon the detection range for each ELISA kit, the supernatant
MMPs in Diabetic Retinopathy
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vitreous obtained was used either directly or diluted with
calibrator diluents supplied to the ELISA kit.
For the measurement of MMP-2, 50 µL of 10-fold diluted
vitreous were used and added to the respective well of ELISA
plate. For the measurement of VEGF, an amount of 100 µL of
undiluted vitreous fluid was added to each well of the ELISA
plate. The assay was performed in duplicate for each standard
and vitreous sample. Antibody against MMP-2 or VEGF
(conjugated to horseradish peroxidase) was added to each well
of the ELISA plate. After the addition of substrate mix solution,
the reaction was completed with the addition of stop solution
(2N sulfuric acid) to each well of the ELISA plate and
immediately the Optical Density (OD) was read at 450 nm with
the use of a microplate reader with wavelength correction of
540 nm. Using the 4-parameter fit logistic (4-PL) curve
equation for making the standard curves, the actual
concentration for each sample was calculated. For the diluted
vitreous fluid, the correction read from the standard curve
obtained using 4-PL was multiplied by the dilution factor to
obtain the actual reading for each sample.
Zymography
Gelatinolytic levels of MMP-2 and MMP-9 were estimated in
the vitreous fluid by zymography technique [10]. Equal volumes
(10µl) of vitreous samples were mixed with Laemmli’s sample
buffer (1:1, v/v) and were electrophoresed under nonreducing
conditions onto 10% SDS-PAGE gels polymerized with 1
mg/mL gelatin. The gels were washed with 2.5% Triton X-100,
and overnight incubated at 37°C in substrate buffer containing
50 mM Tris-HCl, pH 8.0, 5 mM CaCl2, and 0.02% NaN3. The
gels were stained with Coomassie blue stain (0.5% Coomassie
blue R-250, 5% methanol, and 10% acetic acid), followed by
destaining (5% methanol, 10% acetic acid). The image was
taken with the GeneSys (version 1.2.0.0) software on a G: Box
machine and signal intensities of bands (for MMP-9; ~100 kDa
and for MMP-2; ~70 kDa) were quantified using the GeneTools
software.
Western blot analysis
To determine the expression of MMP-1, MMP-2, MMP-3 and
MMP-9 in the vitreous samples, equal volumes of vitreous
samples were boiled in Laemmli’s sample buffer (1:1, v/v)
under reducing conditions for 10 min. Equal volume of lysis
solution (15 µL) was loaded and separated on 10-15% SDS-
PAGE gels and transferred onto nitrocellulose membranes.
After protein transfer, the membrane was blocked (1.5 h, room
temperature) with 5% non-fat milk and incubated overnight at
4°C with rabbit polyclonal anti-MMP-1 (1:300; Cat No:
sc-30069, Santa Cruz, CA, USA), mouse monoclonal anti-
MMP-2 (1:300; Cat No: ab3158, Abcam, UK) and goat
polyclonal anti-MMP-3 ((1:300; Cat No: sc-30069, Santa Cruz),
mouse monoclonal anti-MMP-9 (1:1000; REGA-2D9, Rega
Institute for Medical Research, University of Leuven, Belgium)
[11]. After incubation with primary antibody, the membranes
were washed and incubated at room temperature for 1.5 h with
their respective secondary horseradish peroxidase-conjugated
antibody. Membranes were again washed four times and the
immunoreactivity of bands was visualized on a high-
performance chemiluminescence machine (G: Box) by using
enhanced chemiluminescence plus Luminol (1:1 v/v, Cat No:
sc-2048, Santa Cruz). Protein bands were quantified by
densitometric analysis using image processing and analysis in
GeneTools software.
Immunohistochemical staining
Endogenous peroxidase in tissue sections was abolished
with 2% hydrogen peroxide in methanol for 20 minutes, and
nonspecific background staining was blocked by incubating the
sections for 5 minutes in normal swine serum. Antigen retrieval
was performed by boiling the sections in 10 mM citrate buffer
[pH 6] for 30 minutes. Subsequently, the sections were
incubated with mouse monoclonal anti-MMP-9 (1:50;
REGA-2D9) and mouse monoclonal anti-CD45 (1:50; Dako,
Glostrup, Denmark) for 60 minutes. Optimal working
concentration and incubation time for the antibodies were
determined earlier in pilot experiments. The sections were then
incubated for 30 minutes with immunoglobulin conjugated to
peroxidase-labeled dextran polymer [EnVision (Flex); Dako,
Carpinteria, CA, USA]. The reaction product was visualized by
incubation for 10 minutes in 0.05 M acetate buffer at pH 4.9,
containing 0.05% 3-amino-9-ethylcarbazole (Sigma-Aldrich,
Bornem, Belgium) and 0.01% hydrogen peroxide, resulting in
bright-red immunoreactive sites. The slides were then faintly
counterstained with Harris hematoxylin. To identify the
phenotype of cells expressing MMP-9, sequential double
immunohistochemistry was performed. Antigen retrieval was
performed by boiling the sections in Tris-ethylene-
diaminetetraacetic acid buffer [pH 9] for 20 minutes, followed
by incubation with anti-CD45 and subsequently treated with
peroxidase conjugated secondary antibody. The sections were
visualized with 3,3’-diaminobenzidine tetrahydrochloride.
Incubation of the second primary antibody anti-MMP-9, was
followed by treatment with alkaline phosphatase conjugated
secondary antibody. The sections were visualized with fast red.
No counterstain was applied. Omission or substitution of the
primary antibody with an irrelevant antibody from the same
species and staining with chromogen alone were used as
negative controls. Sections from patients with glioblastoma
were used as positive controls for the immunohistochemical
staining methods.
Statistical analysis
Data are presented as the mean ± standard deviation. The
non-parametric Mann-Whitney U test was used to compare
means from two independent groups. Pearson correlation
coefficients were computed to investigate correlations between
variables. A p-value less than 0.05 indicated statistical
significance. SPSS version 19.0 (IBM Inc., Chicago, IL) and
program 3S from the BMDP 2007 Statistical Package were
used for the statistical analyses.
MMPs in Diabetic Retinopathy
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Results
Mosaic multiplex ELISA levels of MMPs in vitreous
samples
The levels of seven different MMPs in the vitreous samples
were determined by mosaic multiplex MMPs ELISA assay
(Figure 1A, B). MMP-8 and MMP-13 were not detected in
vitreous samples from patients with PDR (n=16) and
nondiabetic control patients (n=24). Among the MMPs
examined, MMP-1, MMP-2, MMP-3, and MMP-7 were detected
in all vitreous samples from patients with PDR and control
patients without diabetes. MMP-9 was detected in all vitreous
samples from patients with PDR and in 2 of 24 (8.3%) vitreous
samples from nondiabetic patients. The mean levels of MMP-1,
MMP-7 , and MMP-9 in vitreous samples from PDR patients
were significantly higher than those in nondiabetic patients
p=0.001; p=0.009; p<0.001, respectively; Mann-Whitney test)
(Figure 1C). In contrast, levels of MMP-2 and MMP-3 did not
differ significantly between nondiabetic control patients and
PDR patients (Figure 1C).
With the use of a single ELISA assay for MMP-2, we
confirmed that the levels of MMP-2 did not differ significantly
between nondiabetic control patients (n=22) (77.89±55.53
ng/ml) and PDR patients (n=30) (81.085±43.74 ng/ml)
(p=0.581; Mann-Whitney test).
With the use of Western blot analysis, we confirmed that
MMP-1, MMP-2, MMP-3 and MMP-9 were expressed in
vitreous samples from patients with PDR and nondiabetic
control patients (Figure 2).
Zymography levels of MMP-2 and MMP-9 in vitreous
samples
All vitreous samples contained MMP-2 and MMP-9. The
levels of MMP-2 did not differ significantly between nondiabetic
control patients (n=18) (505.4±216.1 scanning units) and PDR
patients (n=18) (540.9±185.6 scanning units ) (p=0.739; Mann-
Whitney test). The mean MMP-9 level in patients with PDR
(392.3±253.6 scanning units) was significantly higher than the
mean level in nondiabetic control patients (168.2±65.0
scanning units) (p=0.011; Mann-Whitney test) (Figure 3).
ELISA levels of VEGF in vitreous samples
VEGF was detected in 28 out of 32 (8.75%) vitreous samples
from patients with PDR, and in 3 out of 24 (1.25% ) samples
from nondiabetic control patients. Mean VEGF level in vitreous
samples from PDR patients (1.46±1.43 ng/ml) was significantly
higher than the mean level in nondiabetic control patients
(0.037±0.095 ng/ml) (p<0.001; Mann-Whitney test) (Figure 1C).
Correlations
Significant correlations were observed between mosaic
multiplex MMPs ELISA and zymography assays for
quantitation of MMP-2 (r=0.407; p=0.039) and MMP-9 (r=0.711;
p<0.001). In addition, there was a significant correlation
between single ELISA and zymography assays for the
quantitation of MMP-2 (r=0.726; p<0.001). There was a
significant correlation between mosaic multiplex MMPs ELISA
and single ELISA for quantitation of MMP-2 (r=0.701; p<0.001).
Significant correlations were found between vitreous fluid
levels of VEGF and levels of MMP-1 (r=0.845; p<0.001) and
MMP-9 (r=0.775; p<0.001). There was a significant correlation
between vitreous fluid levels of MMP-1 and MMP-9 (r=0.857;
p<0.001) (Figure 4). In addition, MMP-9 zymography levels
correlated significantly with vitreous fluid levels of MMP-1
(r=0.856; p<0.001) and VEGF (r=0.872; p<0.001).
Immunohistochemical analysis
No staining was observed in the negative control slides
(Figure 5A). Immunoreactivity for MMP-9 was present in all
membranes and was detected in the cytoplasm of stromal
cells, intravascular leukocytes and vascular endothelial cells
(Figure 5B, C). The majority of MMP-9-positive stromal cells
were monocytes/macrophages and neutrophils. In serial
sections, the distribution and morphology of stromal cells
expressing MMP-9 were similar to those of cells expressing the
leukocyte common antigen CD45 (Figure 5D). Double staining
confirmed that stromal cells expressing MMP-9 co-expressed
CD45 (Figure 5E).
Discussion
Aside the technological aspects by which various protein
measurement methods were validated and corroborated, four
key findings emerged from this study. First, of the three
collagenases (MMP-1, MMP-8 and MMP-13), only MMP-1 was
detected in the vitreous fluid from nondiabetic control patients
and patients with PDR. Furthermore, MMP-1 was significantly
upregulated in the vitreous fluid from patients with PDR.
Second, of the gelatinases (MMP-2, and MMP-9), MMP-9, but
not MMP-2, was significantly increased in vitreous samples
from eyes with PDR compared with those of nondiabetic
patients. Third, MMP-7 levels in the vitreous fluid from patients
with PDR were significantly higher than those in nondiabetic
patients. Fourth, there were significant positive correlations
between the levels of VEGF and the levels of MMP-1 and
MMP-9. Collectively, these findings indirectly suggest that in
PDR, MMP-1 and MMP-9 may play an important role in the
progression of angiogenesis associated with PDR.
MMP-1 is an interstitial collagenase that is often upregulated
in several types of cancer, and this enzyme is involved in
tumor-induced angiogenesis [12-15]. Several studies
demonstrated that enhanced MMP-1 expression increased
angiogenic activity in tumors [12-15], and that tumor-derived
MMP-1 stimulates endothelial cell activation and promotes
complex tube formation in vitro [13,14]. In addition, attenuation
of MMP-1 expression reduced tumor-induced angiogenesis in
vivo [14]. Furthermore, MMP-1 acts directly on human
microvessel endothelial cells as a pro-angiogenic signaling
molecule and induces the expression of different subsets of
pro-angiogenic genes. Purified MMP-1 is also capable of
inducing angiogenesis in vivo in a controlled Matrigel system,
thereby defining MMP-1 as a pro-angiogenic factor [16].
Several studies demonstrated the presence of a positive
feedback regulation between MMP-1, MMP-9 and VEGF.
MMPs in Diabetic Retinopathy
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Figure 1.  A. Well map indicating the spot locations of the analytes detected using the mosaic ELISA Human MMP Panel. The
reference spot provides a strong positive signal for easy visualization of the well locations and spot alignment during data
Analysis. B. Representative images of individual wells for the standard curve (left lane) and series of eight samples from nondiabetic
control patients (C) and eight proliferative diabetic retinopathy (PDR) patients. C. Comparison of mean mosaic multiplex
metalloproteinase (MMPs) enzyme-linked immunosorbent assay levels and vascular endothelial growth factor (VEGF) levels
between proliferative diabetic retinopathy (PDR) patients and nondiabetic control patients. *The difference between the two means
was statistically significant at 5% level of significance.
doi: 10.1371/journal.pone.0085857.g001
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VEGF stimulation significantly enhanced production of MMP-1
and MMP-9 by immortalized human chondrocytes [17] and
human vascular smooth muscle cells [18]. MMP-1 induces
MMP-9 expression in human microvessel endothelial cells [16]
and macrophages [19]. In agreement with these studies, we
demonstrated significant correlations between the levels of
MMP-1 and the levels of MMP-9 and VEGF in the vitreous
fluid.
In the present study, MMP-7 levels in the vitreous samples
from eyes with PDR were significantly increased as compared
to nondiabetic control patients. MMP-7 contributes to
angiogenesis by breaking down basement membranes. MMP-7
expression was demonstrated in endothelial cells of various
tumors and was associated with decreased survival suggesting
that MMP-7 is involved in tumor angiogenesis [20].
Furthermore, MMP-7 has been shown to accelerate the
proliferation of human umbilical vein endothelial cells in a dose-
dependent manner in vitro suggesting that MMP-7 can directly
induce angiogenesis [21]. Recently, it was demonstrated that
MMP-7 degrades soluble VEGF receptor-1 resulting in the
escape of VEGF from sequestration by soluble VEGF
receptor-1. These findings provide a mechanism for the
regulation of VEGF bioavailability within the local endothelial
microenvironment [22].
MMP-9 expression is low or absent in most normal tissues,
and it is markedly elevated during inflammatory, autoimmune,
degenerative and neoplastic diseases and angiogenic lesions
[23]. On the other hand, expression of MMP-2 is constitutive
and most proinflammatory stimuli fail to increase the
expression level of MMP-2 [1,23]. In the present study,
zymography analysis and ELISA assays confirmed previous
studies reporting that MMP-9, but not MMP-2, is increased in
the vitreous fluid from patients with PDR compared with those
of nondiabetic patients [6,8,9]. However, it was reported by
Figure 2.  Representative Western blot analysis of matrix
metalloproteinase-1 (MMP-1), MMP-2, MMP-3 and MMP-9 in
vitreous samples from three proliferative diabetic
retinopathy (PDR) and three nondiabetic control (C)
patients.  
doi: 10.1371/journal.pone.0085857.g002
Noda et al. [7] that MMP-2 is also significantly increased in
vitreous samples from patients with PDR. Our findings suggest
that MMP-2 apparently does not significantly contribute to the
angiogenic switch in PDR. Our findings are consistent with
previous studies using animal models of cancer that indicated
that MMP-2 apparently does not significantly contribute to the
angiogenic switch [1]. Our analysis showed a significant
positive correlation between the vitreous levels of VEGF and
MMP-9. VEGF is a critical regulator of angiogenesis that
stimulates proliferation, migration, and proteolytic activity of
endothelial cells [24]. Similarly, previous studies reported a
strong correlation between the expression of VEGF and
MMP-9, but not with MMP-2, in cancer patients [3,25,26], and
in the synovial fluid of patients with rheumatoid arthritis [27].
This correlation is consistent with preclinical data reporting the
presence of a positive feedback regulation between VEGF and
MMP-9. VEGF treatment can induce MMP-9, but not MMP-2
expression in different cells [18,28]. Conversely, exogenous
MMP-9 increased the secretion of VEGF, whereas MMP-2
reduced the secretion of VEGF [28].
Growing evidence indicates that inflammatory cells, including
monocytes/macrophages and neutrophils, constitute a major
cellular source of the proangiogenic MMP-9 and contribute to
tumor angiogenesis [3,29,30]. Inflammatory neutrophils deliver
unique TIMP-1-free proMMP-9, which in turn rapidly and
potently triggers the angiogenic switch in tumors [30-32]. In the
present study, we described the in situ localization of the
expression of MMP-9 in leukocytes expressing the leukocyte
common antigen CD45 and endothelial cells in epiretinal
membranes from patients with PDR. Previous studies
demonstrated that activated endothelial cells over-express
MMP-1 and MMP-9 during sprouting and formation of lumina-
containing tubules [1].
The vitreous fluid, collected from patients with PDR during
pars plana vitrectomy, is an ideal material for analysis of local,
intraocular concentrations of selected proteins which take part
of this pathology. However, when measuring these factors in
the vitreous, some considerations should be kept in mind.
Vitreous hemorrhage, associated with active
neovascularization or traction on the retina induced by
involuted fibrovascular proliferation during posterior vitreous
detachment, can provide an influx of serum proteins into
vitreous fluid. In a previous study, we demonstrated that there
was no correlation between hemoglobin levels, as a measure
of the amount of erupted blood, and total protein levels in
vitreous fluid from patients with PDR [6]. Although VEGF is
abundant in serum, the levels of VEGF in the vitreous fluid did
not differ significantly between eyes with massive vitreous
hemorrhage without diabetic retinopathy and nondiabetic eyes
without vitreous hemorrhage. On the other hand, the
concentration of VEGF was significantly higher in eyes with
PDR than in nondiabetic eyes with massive vitreous
hemorrhage or nondiabetic eyes with no vitreous hemorrhage
[33]. Moreover, in a previous study, we reported that brain-
derived neurotrophic factor (BDNF) was not detected in
vitreous samples from patients with PDR and nondiabetic
control patients, whereas BDNF was detected in all serum
samples from patients with PDR and nondiabetic controls [34].
MMPs in Diabetic Retinopathy
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In the present study, we demonstrated the expression of
MMP-9 by vascular endothelial cells and stromal cells in PDR
fibrovascular epiretinal membranes. These findings suggest
that local cellular production is the relevant source of the
studied factors within the ocular microenvironment and that
systemic inflow mechanism is rather improbable.
In conclusion, among all the MMPs measured, only MMP-1
and MMP-9 significantly positively correlated with VEGF.
These results suggest that both MMP-1 and MMP-9 contribute
to the angiogenic switch critical for PDR progression.
Combination therapy of VEGF inhibitors with MMP inhibitors
may be useful in the treatment of PDR and other retinal
diseases with pathological angiogenesis.
Figure 3.  Gelatin zymography of the vitreous samples.  Representative zymography of the vitreous samples from four
nondiabetic control (C) patients and four patients with proliferative diabetic retinopathy (PDR) patients. Gelatinolytic bands of ~100
and ~70 kDa correspond to MMP-9 and MMP-2, respectively.
doi: 10.1371/journal.pone.0085857.g003
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Figure 4.  Significant positive correlations between vitreous fluid levels of vascular endothelial growth factor (VEGF) and
levels of matrix metalloproteinase-1 (MMP-1) (A) and MMP-9 (B) and between vitreous fluid levels of MMP-1 and MMP-9 (C)
in vitreous samples from 16 proliferative diabetic retinopathy and 24 nondiabetic control patients analyzed with mosaic
multiplex matrix metalloproteinase (MMPs) enzyme-linked immunosorbent assay.  
doi: 10.1371/journal.pone.0085857.g004
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Figure 5.  Proliferative diabetic retinopathy epiretinal membranes.  Negative control slide that was treated identically with an
irrelevant antibody showing no labeling (A). Immunohistochemical staining matrix metalloproteinase-9 (MMP-9) showing
immunoreactivity in endothelial cells (arrows), intravascular leukocytes (B) and stromal cells (C). Immunohistochemical staining for
CD45 showing immunoreactivity in leukocytes expressing the leukocyte common antigen CD45 (D) Double immunohistochemistry
for CD45 (brown) and MMP-9 (red) showing cells co-expressing CD45 and MMP-9 (arrows). No counterstain was applied (E)
(original magnification X40).
doi: 10.1371/journal.pone.0085857.g005
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